DVA DaVita
Intrinsic value$263.41
Price (at call)$176.01
Margin of safety
+49.7%
vs market (rating basis)
+143.3%
Model unavailable; showing baseline valuation.
⚠ LLM error: unbalanced JSON in response: '{\n "story": "DaVita is a mature duopolist in U.S. dialysis — an essential, recurring-care business with scale advantages over smaller rivals, but a payer mix dominated by government rates and no real'; using baseline
The story
Value drivers
| Revenue growth (Y1) | 5.5% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 14.4% |
| Years to target margin | 5 |
| Sales-to-capital | 1.44 |
| Beta | 0.87 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 7.7% |
| Terminal WACC | 8.0% |
Valuation bridge
| PV of explicit FCFF | 9.85B |
| PV of terminal value | 19.79B |
| Equity value | 16.81B |
| ÷ shares → per share | $263.41 |
News
bullish +0.30 · 8 articles
- There Was No Beating Moderna in August. These Are the Best and Worst S&P 500 Stocks for the Month.
- Zacks Industry Outlook Highlights DaVita, LifeStance Health, Option Care Health, and Aveanna Healthcare
- 4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds
- How CVS' Pharmacy & Consumer Wellness Is Positioned for H2 2026
- DVA & Humana Expand Value-Based Care for Kidney Disease Patients
- Can Humana (HUM) Stay Cheap If Medicare Advantage Margins Tighten?
- DaVita and Humana Expand Kidney Care Partnership to More Than 10,000 Patients
- Berkshire Adds to Alphabet Stake, Buys Home Builders and Exits Constellation
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 14.60B | 5.5% | 14.4% | 1.64B | 531.76M | 1.11B | 1.03B |
| 2 | 15.37B | 5.3% | 14.4% | 1.73B | 538.28M | 1.19B | 1.03B |
| 3 | 16.15B | 5.1% | 14.4% | 1.82B | 542.75M | 1.28B | 1.02B |
| 4 | 16.94B | 4.9% | 14.4% | 1.91B | 545.00M | 1.36B | 1.01B |
| 5 | 17.72B | 4.6% | 14.4% | 2.00B | 544.91M | 1.45B | 1.00B |
| 6 | 18.50B | 4.4% | 14.4% | 2.08B | 542.37M | 1.54B | 986.92M |
| 7 | 19.27B | 4.2% | 14.4% | 2.17B | 537.27M | 1.63B | 970.99M |
| 8 | 20.03B | 4.0% | 14.4% | 2.26B | 529.52M | 1.73B | 953.05M |
| 9 | 20.78B | 3.7% | 14.4% | 2.34B | 519.06M | 1.82B | 933.22M |
| 10 | 21.51B | 3.5% | 14.4% | 2.42B | 505.86M | 1.92B | 911.63M |